Drug profile · INN
ipilimumab
YERVOY
ipilimumab (YERVOY) is a cytotoxic t-lymphocyte protein 4 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — ipilimumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 6
- Programs
- 50
- Data quality
- 0.84
Quick answer
ipilimumab (YERVOY) is a cytotoxic t-lymphocyte protein 4 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytotoxic T-lymphocyte protein 4 inhibitor
Primary target: Cytotoxic T-lymphocyte protein 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 11534488
Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
granted -
US 10800853
Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
granted -
US 10385136
Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
granted -
US 9790271
Methods for increasing immunoglobulin A levels
granted -
US 9598495
Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
granted -
US 9249227
Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
granted
Frequently asked questions
What is ipilimumab?
ipilimumab (YERVOY) is a cytotoxic t-lymphocyte protein 4 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ipilimumab?
YERVOY is a marketed brand name for ipilimumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ipilimumab?
ipilimumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.